01/03/2025
Health authorities in Europe are probing whether Ozempic and similar weight loss drugs may cause blindness, following studies linking them to a rare eye condition.
Harvard researchers flagged concerns in 2023 after three patients using Ozempic developed non-arteritic anterior ischemic optic neuropathy (NAION) within a week. This condition disrupts blood flow to the optic nerve, potentially leading to blindness. Their findings showed Ozempic users had double the risk of developing NAION.
Recent Danish studies have strengthened this connection, prompting the Danish government to request a formal investigation by the European Union. Researchers in Denmark found that while the absolute risk remains low, Ozempic users face a heightened likelihood of developing NAION compared to users of other diabetes drugs.
NAION, which affects around 6,000 Americans annually, is commonly associated with aging, high blood pressure, or smoking. Its connection to Ozempic raises questions, as the drug works primarily by imitating hormones that regulate hunger.
This isn’t the first safety concern tied to Ozempic. Existing warnings highlight risks of thyroid tumors, stomach paralysis, and other side effects like nausea, vomiting, and malnutrition. Some users have also reported suicidal thoughts, sexual dysfunction, and hair loss.
With over 15 million Americans currently using Ozempic or similar drugs, regulators and researchers will be closely watching to determine the full extent of these risks.
👇
https://www.dailymail.co.uk/health/article-14205789/officials-ozempic-cause-blinding-eye-disease-Denmark-EU.html